Agios Pharmaceuticals shares are trading higher after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier's vorasidenib to Royalty Pharma.
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals shares are trading higher after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier's vorasidenib to Royalty Pharma.
May 28, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agios Pharmaceuticals shares are trading higher following the announcement of selling its 15% royalty rights on Servier's vorasidenib to Royalty Pharma.
The sale of royalty rights is perceived positively by investors, leading to a rise in Agios Pharmaceuticals' stock price. This move likely provides immediate financial benefits and reduces future revenue uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100